Studies in the literature are limited both throughout Turkey and in general. For this reason, as a result of the study that we will create, it will provide us with information for bladder protective treatments in patients who do not respond to BCG therapy in bladder cancer patients.
Study Type
OBSERVATIONAL
Enrollment
120
Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
Dokuz Eylul University Faculty of Medicine Department of Urology
Izmir, Other (Non U.s.), Turkey (Türkiye)
Recurrence rate
the recurrence rate after intravesical chemotherapy will be calculated
Time frame: 5 years
Progression rate
the progression rate after intravesical chemotherapy will be calculated
Time frame: 5 years
Adverse effects of intravesical chemotherapy
the patients' data will be retrospectively analyzed to investigate the side effects of intravesical chemotherapy
Time frame: 5 years
Intravesical chemotherapy versus radical cystectomy
the long-term cancer specific survival, overal survival, recurrence free survival of patients with similar pathological characteristics and who underwent radical cystectomy and patients who were given intravesical chemotherapy will be compared
Time frame: 5 years
treatment change
patient transitions from intravesical chemotherapy to other treatment options will be calculated
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.